Adherence to Long-term Adjuvant Hormonal Therapy for Breast Cancer

Carolyn Gotay; Julia Dunn

Disclosures

Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):709-715. 

In This Article

Five-year View

We believe that adherence to endocrine therapies is a subject that will increasingly be given the concerted attention it deserves. We expect that quality-of-life issues will continue to gain prominence alongside disease-oriented outcomes in the minds of both healthcare providers and the patients themselves as information becomes increasingly accessible. We expect to see advancements in the therapies, with new therapies under investigation that carry lesser side-effect profiles, while simultaneously being more efficacious. In addition, we believe that interventions will be developed to ensure more efficacious management of side effects and obstacles to adherence. We are confident that these new developments will help address the barriers that prevent women from receiving the optimal care available to them.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....